Cell Technology Inc. of Boulder, Colo., formed a clinical anddevelopment alliance with Tecnofarma S.A. of Buenos Aires,Argentina, for Cell's biological products, including its anti-cancer product ImuVert.
Tecnofarma's primary focus is on cancer products, and it claimsan 80 percent share of the market for some oncologicalproducts in Latin America.
Tecnofarma and its subsidiaries agreed to clinically develop,test and try to market ImuVert throughout Latin America,except Mexico, where Cell said it has an agreement withLaboratorios Andromaco.
Cell said last week that it agreed to pay $5.5 million for PioneerPharmaceuticals of Irvington, N.J., partly in response todisappointing clinical results for ImuVert, a biologic responsemodifier derived from bacteria. Pioneer is a specialty and over-the-counter drug maker.
(c) 1997 American Health Consultants. All rights reserved.